Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Real World Data on Management of Male LUTS

12 mars 2020 uppdaterad av: Boehringer Ingelheim

Real World Data Exploring the Practices of Primary Care Providers in the Managment of Male Lower Urinary Tract Symptoms

This study will describe the current medical care given to men who discuss their lower urinary tract symptoms with a HCP. It will document the primary reasons for the visit, the baseline characteristics of these men, the treatment received, and the practice patterns of specifically a primary care physician managing these patients.

Studieöversikt

Status

Avslutad

Betingelser

Studietyp

Observationell

Inskrivning (Faktisk)

201

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Kentucky
      • Lexington, Kentucky, Förenta staterna
        • 527.87.10001 Boehringer Ingelheim Investigational Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 100 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Manlig

Testmetod

Sannolikhetsprov

Studera befolkning

men

Beskrivning

Inclusion criteria:

  • Males, aged ≥18 years old.
  • Having had discussion of urinary symptoms with their PCP between 15 days and 12 months prior to the date of the phone interview.
  • Able to read, speak and understand English.
  • Willing to provide informed consent for study participation, authorize the release of their previous 12-month medical records from their PCP for review and de-identified data entry by Mapi into an electronic study database.

Exclusion criteria:

  • Reported during screening that they had had their first-ever discussion of urinary symptoms with PCP within the 14 days prior to the date of the phone interview.
  • Participation in a clinical research study that evaluated urinary symptoms in the past 12 months.
  • Self-reported history of colorectal, bladder or prostate cancer.
  • Self-reported neurologic disorders that affect bladder function, e.g., neurogenic bladder disorders due to spinal cord injury/disease, multiple sclerosis, Parkinsons disease.
  • Self-reported history of radiation therapy to the lower abdominal and/or pelvic region.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: Kohort
  • Tidsperspektiv: Retrospektiv

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records
Tidsram: 12 months

The percentage of men who have been given at least one prescription medication for urinary symptoms.

This included any medications prescribed by PCP for urinary symptoms according to medical records within 12 months prior to telephone survey as described below:

  1. Medications already prescribed by PCP for urinary symptoms prior to the 1st visit/contact for urinary symptoms within 12 months prior to telephone survey.
  2. Medications newly prescribed by PCP upon visit(s)/contact(s) for urinary symptoms within 12 months prior to telephone survey (i.e., medications prescribed for urinary symptoms on or after the 1st visit/contact).

95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The Percentage of Men Who Received a Medical Diagnosis for Their Urinary Symptoms, as Recorded in Their Medical Records.
Tidsram: 12 months

The percentage of men who received a medical diagnosis for their urinary symptoms, as recorded in their medical records.

95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
The Percentage of Men With a Diagnostic Testing Procedure Ordered or Performed Specifically for Their Urinary Symptoms.
Tidsram: 12 months

The percentage of men with a diagnostic testing procedure ordered or performed specifically for their urinary symptoms.

95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
The Percentage of Men Diagnosed With LUTS/BPH (Enlarged Prostate).
Tidsram: 12 months

The percentage of men diagnosed with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) (enlarged prostate).

95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
The Percentage of Men Referred to a Urologist for Their Urinary Symptoms.
Tidsram: 12 months

The percentage of men referred to a urologist for their urinary symptoms.

95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
The Percentage of Men Given a Prescription for an Alpha-blocker for Their Urinary Symptoms.
Tidsram: 12 months

The percentage of men given a prescription for an alpha-blocker for their urinary symptoms.

95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
The Percentage of Men Given Repeat Prescriptions for Their Urinary Symptoms.
Tidsram: 12 months

The percentage of men given repeat prescriptions for their urinary symptoms.

95% CI was calculated using clopper-pearson estimation method based on the exact binomial distribution.
12 months
The Number of Urinary-symptom Related Visits to Their PCP During the 12 Month Period Prior to Telephone Survey Interview.
Tidsram: 12 months
The number of urinary-symptom related visits to their primary care provider (PCP) during the 12 month period prior to telephone survey interview.
12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Boehringer Ingelheim

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

19 maj 2016

Primärt slutförande (Faktisk)

21 december 2016

Avslutad studie (Faktisk)

21 december 2016

Studieregistreringsdatum

Först inskickad

8 mars 2017

Först inskickad som uppfyllde QC-kriterierna

8 mars 2017

Första postat (Faktisk)

9 mars 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

26 mars 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 mars 2020

Senast verifierad

1 mars 2020

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 527.87

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Benign prostatahyperplasi

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Singapore

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera